<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1544</td>
<td>Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype</td>
<td>Jeong KY, Lee H</td>
</tr>
<tr>
<td>1551</td>
<td>New drugs for the treatment of metastatic colorectal cancer</td>
<td>Cherri S, Libertini M, Zaniboni A</td>
</tr>
<tr>
<td>1561</td>
<td>Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer</td>
<td>Mammes A, Pasquier J, Mammes O, Conti M, Douard R, Loric S</td>
</tr>
<tr>
<td>1599</td>
<td>Radiomics in hepatocellular carcinoma: A state-of-the-art review</td>
<td>Yao S, Ye Z, Wei Y, Jiang HY, Song B</td>
</tr>
<tr>
<td>1616</td>
<td>Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development treatment</td>
<td>Bartolini I, Risaliti M, Tucci R, Muisen P, Ringressi MN, Taddei A, Amedei A</td>
</tr>
<tr>
<td>1648</td>
<td>Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers</td>
<td>Lv X, Xu G</td>
</tr>
<tr>
<td>1680</td>
<td>Liver tumors in children with chronic liver diseases</td>
<td>Sintusek P, Phewplung T, Sampavat A, Poovoravan Y</td>
</tr>
</tbody>
</table>
## Contents

**World Journal of Gastrointestinal Oncology**

**Monthly Volume 13 Number 11 November 15, 2021**

### ORIGINAL ARTICLE

#### Basic Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1709</td>
<td>Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis</td>
<td>Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ</td>
</tr>
<tr>
<td>1741</td>
<td>Preventive and inhibitive effects of Yiwei Xiaoyu granules on the development and progression of spasmolytic polypeptide-expressing metaplasia lesions</td>
<td>Chen WQ, Tian FL, Zhang JW, Yang XJ, Li YP</td>
</tr>
<tr>
<td>1755</td>
<td>Effects of dietary zinc deficiency on esophageal squamous cell proliferation and the mechanisms involved</td>
<td>Chen Y, Liu FX, Liu H</td>
</tr>
</tbody>
</table>

#### Case Control Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1766</td>
<td>Genetic variation of TGF-BR2 as a protective genotype for the development of colorectal cancer in men</td>
<td>Stanilov N, Grigorova A, Velikova T, Stanilova SA</td>
</tr>
</tbody>
</table>

#### Clinical Trials Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1781</td>
<td>Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer</td>
<td>Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK</td>
</tr>
</tbody>
</table>

### SYSTEMATIC REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1799</td>
<td>Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review</td>
<td>Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J</td>
</tr>
</tbody>
</table>

### META-ANALYSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1833</td>
<td>Anatomical vs nonanatomical liver resection for solitary hepatocellular carcinoma: A systematic review and meta-analysis</td>
<td>Liu H, Hu FJ, Li H, Lan T, Wu H</td>
</tr>
</tbody>
</table>
LETTER TO THE EDITOR

1847  Hepatocellular carcinoma biomarkers, an imminent need

Zamora-León SP
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Wen-Wei Sung, MD, PhD, Associate Professor, Doctor, Surgeon, Department of Urology, School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Taichung 40201, Taiwan. flutewayne@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.
New drugs for the treatment of metastatic colorectal cancer

Sara Cherri, Michela Libertini, Alberto Zaniboni

Abstract

Colorectal cancer (CRC) represents one of the most frequent malignancies in terms of incidence and mortality, thus representing the third leading cause of cancer death worldwide. In the last decade, few drugs have enriched the treatment landscape of metastatic CRC and have significantly affected prognosis. Unlike other neoplasms, metastatic CRC patients who have exhausted treatment options often still maintain a good performance status. There are many challenges to increasing potential treatment options, notably a better understanding of disease biology and the mechanisms of resistance underlying cancer treatment failure. The development of new drugs for metastatic CRC certainly represents one of the most important challenges in medical oncology. This article discusses the main limitations in the development of new drugs and potential future scenarios. In particular, we addressed three questions: (1) The main limitations of targeted therapy in the treatment of metastatic CRC (mCRC); (2) New target armamentarium that could escape primary and secondary resistance and lead to more personalized mCRC therapy; and (3) Future directions.

Key Words: Colon cancer; Colon rectal cancer; New drugs; Drug resistance; Metastatic colorectal cancer
INTRODUCTION

Targeted therapy has drastically changed the oncological landscape by modifying the natural history of numerous oncological pathologies. Colorectal cancer (CRC) patients were among the first to benefit from the introduction of targeted therapy a decade ago, following a better understanding of the molecular biology of metastatic colorectal cancer (mCRC) and the advent of anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) drugs, such as bevacizumab, cetuximab and panitumumab. This was followed by the introduction of a multikinase molecule, regorafenib. Despite these advances, CRC is still one of the leading causes of cancer-related deaths, being the world’s fourth most deadly cancer, with almost 900000 deaths annually[1]. Furthermore, the 5-year survival for metastatic colon cancer patients to date remains below 15%[2]. For this reason, it is of fundamental importance to enrich the therapeutic scenario of mCRC, and drugs that can impact not only mCRC overall survival but also quality of life are desperately needed.

MAIN LIMITATIONS OF TARGETED THERAPY IN THE TREATMENT OF MCRC

The use of anti-EGFR target drugs, such as cetuximab and panitumumab, and anti-angiogenesis drugs, such as bevacizumab and aflibercept, are consolidated in the clinical practice of metastatic CRC as first- and second-line treatments. Regorafenib is a multikinase drug approved for third-line treatment. In recent years, numerous new agents have emerged that block various critical pathways; however, many studies involving drugs that have led to excellent results in other tumours have not yielded the expected results in the treatment of mCRC. The main causes of treatment failure in mCRC are complex downstream signalling, difficulties in completely inhibiting specific biological interactions for the compensatory activation of other signalling pathways, and innate or acquired resistance to treatment (Figure 1).

An emblematic example of the compensatory activation of other signalling pathways is explained by the history of anti-BRAF drugs in BRAF V600E-mutated mCRC compared to melanoma. Mutations in the Braf isomor, especially V600E, of the RAF protein are present in approximately 5% to 10% of CRCs[3]. The results of BRAF inhibitors in melanoma have led to an enthusiastic development of anti-BRAF/MEK drugs in CRC; however, blockade of BRAF or BRAF/MEK did not lead to a gain in PFS (progression-free survival) or OS (overall survival) of metastatic CRC patients, although it did result in inhibition of downstream MAPK activity[4]. A possible explanation is that blocking BRAF/MEK could trigger EGFR feedback reactivation, which would bypass MAPK activation via RAS[5]. Based on this evidence, subsequent studies have focused on the combined use of BRAF inhibitors and EGFR inhibitors[6], ultimately leading to FDA and EMA approval of the combination encorafenib, binimetinib and cetuximab in second- or third-line mCRC. This indication is the result of the BEACON study, which demonstrated a benefit in terms of overall survival (OS: 9 vs 5.4 mo, HR = 0.52, P < 0.001) and response rate (RR: 26% vs 2%, P < 0.01) with a good safety profile[7].

Innate and acquired resistance mechanisms are very complex and affect both anti-EGFR and anti-VEGF drugs. Concerning anti-EGFR drugs, the main known mechanisms of resistance are RAS mutations, PI3K mutations, PTEN loss, HER2 overexpression, and compensative activation of alternative pathways.

HER2 is a protein member of the Erb family (erythroblastosis oncogene B Erb)/human epidermal growth factor receptor HER). In patients with CRC, the HER2 overexpression rate is 2%-3% and it is independent of the RAS or RAF mutation. HER2 acts similarly to EGFR (HER1), sharing many downstream pathways, such as RAS/RAF/MEK and PI3K/AKT. For this reason, HER overexpression provides a logical explanation for anti-EGFR resistance[8]. Preclinical and clinical studies have shown that combined targeting of HER2 and EGFR can lead to a better result than
those gained with the use of a single agent alone. For Her2-overexpressing disease, unlike in breast cancer, the single inhibition of her2 does not seem to be effective in mCRC, which is likely linked to compensatory mechanisms and the activation of other pathways. Further research is needed to better understand the clinical significance of HER2 gene amplification in mCRC. An illustrative example has been reported in MyPathway, a clinical trial investigating the activity of pertuzumab + trastuzumab in patients with HER2-amplified mCRC, in which eight (8/57) patients had no response.

Compensatory activation of alternative pathways, such as c-MET, VEGF, insulin-like growth factor receptor 1 (IGF-1R), and JAK/STAT, could be linked to acquired resistance to anti-EGFR drugs.

Regarding antiangiogenic drugs, there are currently three approved drugs for mCRC: bevacizumab, a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF-A) administered as a first- and second-line treatment; aflibercept, a recombinant fusion protein composed of fragments of VEGF receptors fused with the Fc portion of human IgG1 approved for second-line treatment; and regorafenib, an oral multikinase inhibitor approved for third-line treatment. There are several intrinsic and secondary known resistance mechanisms for antiangiogenic drugs.

In particular, these resistance mechanisms underlie the difficulty in translating preclinical successes into actual clinical advantage. For example, unlike preclinical studies, bevacizumab improves clinical outcomes only when combined with chemotherapy, with a short disease response to the withdrawal of antiangiogenic drugs, as tumour vessels rapidly grow back after stopping treatment. Compensatory mechanisms in antiangiogenic drug-resistant disease could be the upregulation of growth factors such as TGF-β, IL-1, and macrophage migration inhibitory factor (MIF) and the overexpression of other growth factor receptors such as PDGFR.

Ultimately, the complexity of intrinsic and secondary resistance mechanisms in the targeted treatment of patients with metastatic CRC makes this pathology a challenging oncological dilemma.

**NEW TARGET ARMAMENTARIUM THAT COULD ESCAPE PRIMARY AND SECONDARY RESISTANCE AND LEAD TO MORE PERSONALIZED MCRC THERAPY**

Primary and secondary drug resistance represents the main limitation of CRC care, especially concerning targeted therapies; however, new promising drugs and drug combinations are expected to modify this complex scenario.
As mentioned before, patients with the BRAF V600E mutation have a worse prognosis, and the median overall survival (OS) is less than 1 year vs 2 years for patients without the non-BRAF V600E mutation[3]. In the phase III study BEACON trial, the small molecule BRAF V600E inhibitor encorafenib was combined with binimetinib, a MEK1/2 inhibitor, and cetuximab. The trial showed improved overall survival in both the triplet arm (ceuximab, binimetinib and encorafenib) and doublet arm (cteuximab and encorafenib). The median OS was 9.0 and 8.4 mo, respectively; however, the PFS was approximately 4 mo in both arms[7]. A possible explanation for this short PFS could be the reactivation of MEK and ERK signalling. An ERK 1/2 inhibitor, ulixertinib, is under investigation in a phase I trial, although data from a CRC cohort have not been reported[14].

The EGFR family also includes the HER2 receptor. Activating alterations of this receptor have been detected in approximately 2%-3% of RAS and RAF wild-type colon cancer cases[15]. Many phase II trials have explored the potential use of HER2 inhibitors in mCRC, including a combination of drugs such as trastuzumab and lapatinib in the HERACLES trial[16], trastuzumab and tucatinib, an orally administered HER2-3 inhibitor, in the MOUNTANEER trial[17], and pertuzumab and trastuzumab-emtansine (TDM1) in the HERACLES-B trial[18]. All these trials showed potential activity in terms of ORR and PFS in pretreated metastatic CRC HER2-amplified patients with the combination of Her2 inhibitor blockade. To date, no drugs have been approved for Her2-amplified CRC.

New promising molecules are also being explored in the VEGF inhibitor setting. In particular, a multicentre phase III study, FRESCO-2, comparing placebo vs fruquintinib (NCT04322539), is ongoing. Fruquintinib is a highly selective small molecule inhibitor of VEGFR 1, 2, 3[19]. In the first FRESCO trial, the fruquintinib group showed a median OS of 9.3 mo vs 6.6 in the placebo group (P < 0.001) and a PFS of 3.7 mo vs 1.8 mo. Due to the encouraging results obtained with this trial in China, it has been extended and is now recruiting in Europe and the United States[20].

Current studies are also investigating the potential role of the combination of VEGF with conventional chemotherapy. Trifluridine/tipiracil (TAS-102) was associated with bevacizumab in a phase II study of 93 patients. The association improved both PFS and OS compared with TAS-102 alone[21]. Trifluridina/tipiracil is under investigation with many other drugs, probably due to its low toxicity profile and the absence of cross-resistance with 5-fluorouracil in pretreated patients.

Another crucial new perspective for patients with mCRC is immunotherapy. Currently, immunotherapy has been approved in the United States and will be approved in Europe for patients with microsatellite-deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high), which affects approximately 15% of all patients with mCRC[22]. The clinical trial KEYNOTE 177 comparing pembrolizumab, a PD-1 inhibitor, with standard chemotherapy showed a substantial improvement in PFS with pembrolizumab as the first line in dMMR/MSI-high mCRC[23]. This trial thus represents a practice-changing approach in the first-line therapy of patients with dMMR/MSI metastatic CRC. In the same way, the CheckMate 142 phase II trial investigated the association of nivolumab and ipilimumab in pretreated dMMR/MSI metastatic CRC. The combined treatment, such as for melanoma cancer, showed high response rates and favourable progression-free survival and OS at 12 mo with a low toxicity profile[24].

Unfortunately, immunotherapy is a missed opportunity for patients with proficient mismatch repair and microsatellite stable (pMMR/MSS) mCRC. Many ongoing studies are exploring the possibility of combining immune checkpoint inhibitors with VEGF inhibitors to enhance lymphocyte activation. In preclinical models, VEGF inhibitors showed synergistic action with immune checkpoint inhibition[25]. Based on this evidence, regorafenib was combined with nivolumab in a phase Ib trial (REGONIVO) in patients with refractory metastatic gastric and CRC, obtaining a median PFS of 5.6 and 7.9 mo, respectively[26]. Similarly, in the REGOMUNE phase II trial, the combination of regorafenib and avelumab showed a median progression-free survival of 3.6 mo and overall survival of 10.8 mo[27]. Bevacizumab has been combined with atezolizumab and the triplet chemotherapy regimen FOLFOXIRI (oxaliplatin, irinotecan and 5-fluorouracil) in the AtezoTRIBE trial for patients with unresectable or metastatic CRC. The results are not yet available[28].

Recent data showed a promising combination of avelumab and cetuximab in a rechallenge strategy for RAS and RAF wild-type mCRC patients. In a preliminary analysis, the CAVE study showed a median OS of 13.1 mo and a median PFS of 3.6 mo [29].
The complexity of the resistance mechanisms, multiple escape pathways and disease biology make metastatic CRC a challenging disease in terms of therapeutic strategies. Fortunately, patients with mCRC maintain a good performance status even during disease progression. A very large number of new drugs or combinations are under investigation to reach an even more personalized cancer cure.

### FUTURE DIRECTIONS

Currently, negative predictive markers for the response to EGFR-targeted therapies (KRAS, NRAS mutations), anti-BRAF targeted therapies (BRAF mutation) and positive predictive markers for immune checkpoint inhibitors (microsatellite instability) are standard of care in the treatment of mCRC. In all the main arms of medical oncology, the future seems to lead towards a great and ambitious goal represented by personalized medicine. A large area of research is concentrated on this trend, focusing on next-generation sequencing (NGS)\([30]\) (Table 1).

According to the European Society for Medical Oncology (ESMO) guidelines, in colon cancers, NGS could be an alternative to PCR\([31]\). This method has led to the identification of mutations that could explain greater resistance to standard treatments \([32,33]\) as well as new targets whose therapeutic effects are being studied.

Concerning the use of NGS to identify patients who are likely to respond to standard treatments, few interesting studies have been conducted. One example is the study conducted by Innocenti and colleagues that analysed the response to standard treatments with cetuximab or bevacizumab-based regimens and the results that emerged from NGS. Mutated genes that conferred worse overall survival (OS) than wild-type (WT) tumours and mutations that conferred better survival were highlighted. For example, FANC1-mutated tumours (4%) conferred worse OS than WT tumours \([HR 2.0 (1.2–3.3), P = 0.005; OR 5.0 (1.9–14.8), P = 0.002]\)\([34]\). These findings are very interesting, as they could provide new genes that could become predictors of response to chemotherapy regimens with cetuximab and bevacizumab combinations. If validated in other phase III trials, these mutated genes could be used to guide treatment decisions in mCRC patients.

Another interesting ongoing trial is the COLOMATE umbrella trial, which uses the genomic profiling Guardant360 NGS assay, a plasma-based assay of more than 70 genes, to detect colorectal tumour cfDNA to assign patients with advanced CRC to specific targeted treatment arms based on the molecular profiles of their tumours (NCT03765736). It is fascinating to think that this approach could become our clinical practice in the very near future.

Listed below are some new targets we believe could represent a potential innovation in the near future: KRAS, PI3K, NTRK fusions, ALK, ROS1, RET, and FGFR.

KRAS and NRAS mutations occur in a consistent percentage of mCRC cases (approximately 50% of cases) and identify tumours with a poor prognosis. Mutated KRAS tumours are also inherently resistant to anti-EGFR drugs. KRAS is considered a challenging therapeutic target (Cox AD). Nevertheless, among the different RAS mutations, the KRAS pG12C mutation, which represents approximately 1%–4% of RAS mutations in CRC\([35]\), has been considered potentially druggable. In particular, KRAS-dependent signalling is inhibited by binding to a pocket near the nucleotide binding site and locking it in an inactive guanosine diphosphate (GDP)-bound state \([36]\). Two drugs are currently under investigation in colon cancer, sotorasib (AMG510) and adagrasib (MRTX849). The first phase I study, CodeBreack100, investigated the activity of sotorasib in 129 pretreated patients with the KRAS G12C mutation, including 42 patients with mCRC\([37]\). In the colorectal cohort, the overall response rate (ORR) was 7.1% and the disease control rate was 73.8% (DCR). The median duration of stable disease was 4 mo. Overall, these results were considered disappointing in terms of quality, duration, and adaptive signalling response to drug treatment. The authors postulated that KRAS G12C-mutant cancer cells may still become activated upstream of EGFR\([38]\). For this reason, ongoing studies combining KRAS G12C inhibitors and EGFR inhibitors, such as the randomized phase 3 clinical trial comparing MRTX849 in combination with cetuximab vs chemotherapy in patients with advanced CRC, KRYS\([39]\), are ongoing.

Another fundamental oncological driver in CRCs is the PTEN/P13K/mTOR pathway (20% of cases). The presence of the PI3K mutation confers resistance to anti-EGFR treatments. For this reason, combinations of PI3K oral inhibitors with cetuximab are being studied. This approach, which has been successful in patients with a BRAF
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Phase of study</th>
<th>Primary objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLOMATE trial</td>
<td>NCT03765736 Specific targeted treatment arms based on the molecular profiles</td>
<td>Phase II prospective trial</td>
<td>(1) To perform blood-based genomic profiling on patients with treatment refractory metastatic colorectal cancer (CRC) to facilitate accrual to molecularly assigned therapies; and (2) To facilitate clinically annotated genomic analyses</td>
</tr>
<tr>
<td>CALGB (Alliance)/SWOG 80405</td>
<td>NCT00265850 Bevacizumab or cetuximab combined with the same chemotherapy</td>
<td>Phase III, randomized, open-label, multicentre study</td>
<td>To determine if the addition of cetuximab to FOLFIRI or FOLFOX chemotherapy prolongs survival compared to FOLFIRI or FOLFOX with bevacizumab in patients with untreated, advanced or metastatic colorectal cancer who have K-ras wild type tumours</td>
</tr>
<tr>
<td>KRYSAL 10</td>
<td>NCT04793958 MRTX849 (inhibitor of KRAS G12C)</td>
<td>Phase III, open-label, randomized</td>
<td>Comparing the efficacy of MRTX849 administered in combination with cetuximab vs chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation</td>
</tr>
<tr>
<td>C-PRECISE-01</td>
<td>NCT04495621 MEN1611 + Cetuximab</td>
<td>Phase Ib/II, open-label, multicentre study</td>
<td>MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, S-FU and Anti-EGFR Containing Regimens</td>
</tr>
<tr>
<td>NAVIGATE</td>
<td>NCT0343313 Trastuzumab+tucatinib</td>
<td>Phase II open label study</td>
<td>Tucatinib combined with trastuzumab in patients with HER2+ metastatic colorectal cancer</td>
</tr>
<tr>
<td>NAVIGATE</td>
<td>NCT03576431 Larotrectinib</td>
<td>Phase II open label study</td>
<td>Investigate the efficacy of larotrectinib for the treatment of advanced solid tumours harbouring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults</td>
</tr>
<tr>
<td>NAVIGATE</td>
<td>NCT03829410 Onvansertib (PCM-075)</td>
<td>Phase Ib/II open label study</td>
<td>Determine the safety and efficacy of Onvansertib in combination with FOLFIRI + Avastin, as second-line treatment in adult patients who have metastatic colorectal cancer with a Kras mutation</td>
</tr>
<tr>
<td>MAVEN</td>
<td>NCT02568267 Entrectinib (RXDX-101)</td>
<td>Phase 2 basket study</td>
<td>Treatment of patients with Locally Advanced or metastatic solid tumours that harbour NTRK1/2/3, ROS1, or ALK gene rearrangements</td>
</tr>
<tr>
<td>MAVEN</td>
<td>NCT03724851 Vactosertib (TGF-β receptor I kinase inhibitor) + pembrolizumab</td>
<td>Phase 2, open label study</td>
<td>Safety, tolerability, pharmacokinetics and antitumour activity of vactosertib in combination with pembrolizumab in patients with mCRC including CMS4 or diffuse GC/GEJC</td>
</tr>
</tbody>
</table>

EGFR: Epidermal growth factor receptor; TGF-β: Transforming growth factor-β.

mutation[7], another driver that confers resistance to treatments with anti EGFR, could be applicable in patients with a PI3K mutation[39].

Neurotrophic receptor tyrosine kinase (NTRK) fusions are chromosomal abnormalities that result in uncontrolled TRK signalling that can lead to cancer. NTRK fusions can be identified with NGS, immunohistochemistry (IHC), polymerase chain reaction (PCR), and fluorescent in situ hybridization (FISH) techniques. NTRK fusion-positive mCRC is rare (0.9%)[40]. For this reason, a clinical indication to seek the presence of a NTRK fusion is lacking; however, with increasingly accessible NGS, this target will be necessary to evaluate. In mCRC, NTRK fusions are more frequent in elderly patients, in females, and in right-sided tumours. From the point of view of molecular biology, they are often associated with MSI-H, RAS and BRAF wild-type, as well as poor prognosis with a median overall survival (OS) of approximately 15 mo[41]. Regarding the efficacy of treatments with the oral TRK-selective inhibitors larotrectinib and entrectinib, registration studies of these two molecules, including a very low number of patients with mCRC (4 patients for larotrectinib and only 1 patient for entrectinib), are scarce given the rarity of NTRK fusion in colon cancer; however, the data are encouraging. For example, in the 4 patients included in the single-arm
study that evaluated the efficacy of larotrectinib, a partial response and disease control rate were achieved in 2 and 4 cases, respectively[42]. The data are too scarce to draw any conclusions but favourable given the poor prognosis of this category of patients.

Other very rare mutations in mCRC are rearrangements of anaplastic lymphoma kinase (ALK) and v-ros avian UR2 sarcoma virus oncogene homologue (ROS1)[43]. The future use of oral tyrosine kinase inhibitors, such as alectinib and crizotinib, would be possible in patients with mCRC who present such rearrangements. RET (rearranged during transfection) fusions are even rarer in mCRC (2% of cases)[44], although the message is the same: could a mutation, albeit rare, be successfully treated with a specific drug already used in clinical practice for other solid tumours? These are the considerations we will need to be increasingly familiar with in the near future. Unfortunately, we have no data from clinical trials on the use of selective RET inhibitor drugs in mCRC. A case report of a patient with mCRC harbouring a RET fusion treated with a selective RET inhibitor achieved a complete response to the selective RET inhibitor drug RXDX-105 and a significant PFS of 19 mo[45].

Aberrant activation of fibroblast growth factor (FGFR) signalling has been implicated in the development of various cancers, including colon cancer. Several studies have been conducted to validate the efficacy of FGFR inhibitors in mCRC and other solid tumours (NCT04096417, NCT01976741, NCT03410693, NCT03473756).

Given all these data, the use of NGS will be essential in clinical practice for the treatment of mCRC.

CONCLUSION

Limitations in the development of novel CRC drugs are due to the mechanisms of resistance to target treatments, namely, EGFR antibodies and antiangiogenic treatments, which currently represent therapeutic options for mCRC. A better understanding of mCRC molecular biology has elucidated the resistance mechanisms and consequently enabled the development of combined treatments geared towards precision medicine. The advent of new effective therapies has been very slow in CRCs; in fact, the complexity of the mechanisms involved in the carcinogenesis of CRC makes it difficult to use single biological targets for the development of new drugs. Currently, many signs give hope for new potential possibilities in the treatment of this challenging cancer.

REFERENCES


12 Xue YH, Chen YX, Fang JY. Comprehensive review of targeted therapies for colorectal cancer. *Signal Transduct Target Ther* 2020; 5: 22 [PMID: 32926018 DOI: 10.1038/s41392-020-0116-z]


22 Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. *Cancer*


